There are very good reasons that stocks generally gain in value after a company receives %OrphanDrug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock...
Some investors only pay attention to fundamentals. Others put more weight on technical charts. Another way of looking at it is to think of technical as being useful for quick decisions for those good at...
An estimated 250,000-500,000 people experience a %SpinalCordInjury (SCI) annually, with roughly 17,000 new cases in the US and 27,000 in Europe each year, leaving many of those people permanently confined...
Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - July 7, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) ("NurExone" or the "Company") is pleased to announce that, effective July...
Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided...
Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 8, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided...
The patent covers NurExone's ExoPTEN drug compositions and treatment methods for Central Nervous System diseaseHaifa, Israel and Calgary, Alberta--(Newsfile Corp. - January 12, 2023) - NurExone Biologic...
Background Each year, hundreds of thousands of people suffer from spinal cord injury. In addition, poor medical care and the lack of availability of effective treatments contribute to an increase in SCI...
/CNW/ - Representatives from NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX) and their team joined Yossi Boker, TMX Head of Business...